Synapse - Lindsey Roeker

Search Within

Lindsey Elizabeth Roeker

Results (146)

A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)

Meeting Abstract

Kumar, S.; Kapoor, P.; Alencar, A.; Murthy, G. S. G.; Hoffmann, M.; Pagel, J.; Patel, V.; Pauff, J.; Zinzani, P. L.; Le Gouill, S.; more...
Clinical Lymphoma, Myeloma and Leukemia (2022)

Fulltext@MSK | Save

Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation

Meeting Abstract

Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
Blood (2022)

Fulltext@MSK | Save

Real world comparison of bruton tyrosine kinase inhibitors and venetoclax in patients diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma

Meeting Abstract

Roeker, L. E.; Han, Y.; Ryan, K. J.; Teschemaker, A.; Mato, A. R.
Blood (2022)

Fulltext@MSK | Save

A phase 1a/b dose escalation study of the BTK/FLT3 inhibitor luxeptinib in patients with relapsed or refractory B-cell malignancies

Meeting Abstract

Samaniego, F.; Sadiq, A. A.; Mahadevan, D.; Koontz, M. Z.; Villasboas, J. C.; Burke, J. M.; Reid, E. G.; Cherry, M.; Melear, J.; Priego, V.; more...
Blood (2022)

Fulltext@MSK | Save

Comparing acalabrutinib and ibrutinib in the real world: A study of 2,509 patients with chronic lymphocytic leukemia

Meeting Abstract

Roeker, L. E.; DerSarkissian, M.; Ryan, K. J.; Chen, Y.; Wahlstrom, S. K.; Hakre, S.; Yu, L.; Guo, H.; Mato, A. R.
Blood (2022)

Fulltext@MSK | Save

Safety and tolerability of pirtobrutinib monotherapy in patients with B-cell malignancies who were previously intolerant to a covalent BTK inhibitor: Results from the phase 1/2 BRUIN study

Meeting Abstract

Shah, N. N.; Wang, M. L.; Brown, J. R.; Patel, K.; Woyach, J. A.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; Alencar, A. J.; more...
Blood (2022)

Fulltext@MSK | Save

NX-2127-001, first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies

Meeting Abstract

Mato, A. R.; Wierda, W. G.; Ai, W. Z.; Flinn, I. W.; Tees, M.; Patel, M. R.; Patel, K.; O'Brien, S.; Bond, D. A.; Roeker, L. E.; more...
Blood (2022)

Fulltext@MSK | Save

Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders

Meeting Abstract

Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
Blood (2022)

Fulltext@MSK | Save

Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study

Meeting Abstract

Wierda, W. G.; Lewis, D. J.; Ghia, P.; Shah, N. N.; Coombs, C. C.; Cheah, C. Y.; Lamanna, N.; Rhodes, J. M.; Hoffmann, M.; Ma, S.; more...
Blood (2022)

Fulltext@MSK | Save

Pirtobrutinib; A next generation; Highly selective; Non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study

Meeting Abstract

Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Weirda, W. G.; Cheah, C. Y.; Roeker, L. E.; more...
Oncology Research and Treatment (2022)

Fulltext@MSK | Save